Company
United States
Founded: 1979
Employees: 41,000
CEO: Mr. Michael F. Mahoney
$112.32 Billion
USD as of July 1, 2024
Boston Scientific Corporation is a medical devices company. Primarily known for its drug-eluting stent which is used to open clogged arteries, Boston Scientific also designs, manufactures, and markets a number of devices for intervention and surgery in multiple medical specialties including radiology, cardiology, neurovascular intervention, endoscopy, oncology, urology and gynecology.
| Company | Market Cap (USD) |
|---|---|
| Abbott | $178.02 B |
| Stryker Corporation | $126.48 B |
| Medtronic | $98.95 B |
| Edwards Lifesciences Corporation | $55.63 B |
| Shenzhen Mindray Bio-Medical Electronics Co. Ltd | $47.37 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Boston Scientific Corporation has the following listings and related stock indices.
Stock: NYSE: BSX wb_incandescent
Stock: BMV: BSX wb_incandescent
Stock: Bovespa: B1SX34 wb_incandescent
Stock: NYSE: BSX.PR.A wb_incandescent
Stock: XETR: BSX wb_incandescent
Founder(s): John Abele, Founder & Director Emeritus Peter Nicholas, Founder & Director Emeritus
Michael F. Mahoney, Chairman and (CEO) Daniel Brennan, CFO
Revenue: US$9.913 billion (Fiscal Year Ended December 31, 2020)
Operating income: −US$0.080 billion (Fiscal Year Ended December 31, 2020)
Net income: −US$0.082 billion (Fiscal Year Ended December 31, 2020)
Total assets: US$30.777 billion (Fiscal Year Ended December 31, 2020)
Total equity: US$15.326 billion (Fiscal Year Ended December 31, 2020)